Vaxcyte (PCVX) Capital Expenditures (2019 - 2026)
Vaxcyte (PCVX) posted quarterly Capital Expenditures of $2.1 million for Q1 2026, down 61.15% year-over-year from $5.4 million in Q1 2025, and up 6.95% quarter-over-quarter from $2.0 million in Q4 2025.
Vaxcyte (PCVX) Capital Expenditures (2019 - 2026) Analysis & Trends
Vaxcyte (PCVX) has reported Capital Expenditures for 8 consecutive years, with $2.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 61.15% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $4.2 million (down 80.96% YoY), while the FY2025 annual figure was $7.5 million, down 66.39% from the prior year.
- Capital Expenditures advanced to $2.1 million in Q1 2026 per PCVX's latest filing, from $2.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $15.6 million in Q4 2023 and bottomed at -$4.6 million in Q4 2022.
- Historically, Capital Expenditures has averaged $2.8 million across 5 years, with a median of $2.0 million in 2025.
- On a YoY basis, Capital Expenditures climbed as much as 744.73% in 2023 and fell as far as 542.35% in 2023.
- Vaxcyte's Capital Expenditures stood at -$4.6 million in 2022, then soared by 440.43% to $15.6 million in 2023, then slumped by 74.27% to $4.0 million in 2024, then slumped by 51.01% to $2.0 million in 2025, then gained by 6.95% to $2.1 million in 2026.
- Business Quant data shows PCVX's Capital Expenditures at $2.1 million in Q1 2026, $2.0 million in Q4 2025, and -$1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Vaxcyte | 8.41 Bn | 8.41 Bn | - | 83,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 83,000.00 |
| Jun 30, 2026 | 83,000.00 |
| Mar 31, 2026 | 2.11 Mn |
| Mar 31, 2026 | 2.11 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Dec 31, 2025 | 1.97 Mn |
| Sep 30, 2025 | -1.67 Mn |
| Sep 30, 2025 | -1.67 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Jun 30, 2025 | 1.81 Mn |
| Mar 31, 2025 | 5.42 Mn |
| Mar 31, 2025 | 5.42 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Dec 31, 2024 | 4.02 Mn |
| Sep 30, 2024 | 13.13 Mn |
| Sep 30, 2024 | 13.13 Mn |
| Jun 30, 2024 | -399,000.00 |
| Jun 30, 2024 | -399,000.00 |
| Mar 31, 2024 | 5.68 Mn |
| Mar 31, 2024 | 5.68 Mn |